Named-patient import
and shortage substitution
When Taiwan doesn't have the medicine — or has run short of it — we bring it in compliantly: source comparison, TFDA application, GDP transport and delivery tracking.
Three service modules
Named-patient import (NPP)
Apply for medicines unlicensed or unapproved in Taiwan on behalf of a named patient: indication assessment, source comparison, TFDA documentation guidance, import and delivery tracking.
Shortage platform
International substitution for medicines in short supply: register the need, compare suppliers, confirm price and lead time, execute the import — with proactive cover against national shortage alerts.
Investigational / research drug access
Compliance support for investigational and research drug access (expanded access): regulatory pathway, documentation and cross-border coordination.
Do any of these sound familiar?
We understand the urgency and the administrative load behind a clinical shortage or an unmet treatment need.
Shortage or discontinuation
A broken supply chain or a manufacturer leaving the Taiwan market interrupts treatment, with no substitute available.
Complex import regulation
TFDA named-patient applications and hospital IRB review consume a great deal of time outside the clinic.
Orphan and new drugs out of reach
Medicines already launched abroad are not yet approved in Taiwan, leaving patients without a treatment option.
We don't just deliver the medicine — we support the whole course
Conventional distributors stop at delivery. Our service begins when the medicine arrives: every item imported through this platform comes with a dedicated nurse educator (NE) for one full year.
Less load on the physician
The nurse educator handles medication counselling, side-effect monitoring and follow-up reminders, so out-of-clinic tracking no longer falls on the care team.
Better adherence
Through the LINE official account and phone check-ins, patients take the medicine correctly and complete the course, improving outcomes.
Search the import list
The EAP list is compiled from partner suppliers and publicly available market information. The public page shows only ingredient names (INN), dosage forms, therapeutic areas and supply status; suppliers, source countries and pricing are shared in one-to-one enquiries. (All EAP items are named-patient programs and may be imported only with approval from the pharmaceutical regulatory authority.)
Search importable itemsEntirely. We support healthcare institutions in applying to the Taiwan FDA for named-patient import under the Pharmaceutical Affairs Act and the related regulations. All medicines are sourced from qualified manufacturers or authorized distributors.
It depends on the case. Urgent shortages, rare disease and new drug applications follow different routes, covering hospital IRB review, TFDA approval and overseas ordering and logistics — typically weeks to months. We track progress throughout.
We publish only part of our catalogue, for reference. If you need a specific medicine, please contact a specialist.
Register a shortage
Register the shortage under your institution and we'll come back within two business days with viable sources, lead times and pricing.